skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアサービスログインProductLogin
Global Search Configuration
  • Close Icon

About David

Ireland

+11 year(s) experience

David_Wallace_Pharma_Intelligence
Dave Wallace has nearly 10 years experience of reporting on the global generic, biosimilar, value-added and OTC medicines industries.
Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.

Specialties

  • Biopharma Pipeline Strategy
  • Biosimilars
  • Biotech
  • Commercial Strategy
  • Generics

David writes For

Analyst Articles

Articles by David

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    European Biosimilars Can Benefit From Sharing Experiences

    GB2104_Europe_Connections_Map_Space_2A9CJEX_1200

    Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    EU Reforms Must Heed Pandemic Lessons

    Covid19 Eu reforms

    Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

    Topic Coronavirus EU Policy & Regulation

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    European Industry Played Key Role In Mitigating COVID-19

    In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

    Topic Coronavirus Manufacturing

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Remdesivir Compulsory Licensing Is A Dead End For Europe

    In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

    Topic Coronavirus Intellectual Property policy-and-regulation

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    European Coronavirus Planning Requires ‘Structured Dialog’

    European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

    Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

    Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

    Topic company-analysis

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Two New Categories Join GGB Awards In 2019

    Two New Categories Join GGB Awards In 2019

    Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.

    Topic biopharmaceutical biosimilars

    View article